----

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549 **

**FORM      10-QSB**

**A            J&J PHARMA CORPORATION**

|  NEVADA                                                                              |  86-1024812                                          |
|-------------------------------------------------------------------------------------------|-----------------------------------------------------------|
|  (State                      or other jurisdiction of incorporation or organization) | (I.R.S.                      Employer Identification No.) |

----

**A          J&J PHARMA CORPORATION**

**(A          DEVELOPMENT STAGE COMPANY)**

|   TABLE                  OF CONTENTS |
|------------------------------------------------|
|                                           |   |   |   |   |   |   |   |   |
|                                           |   |   |   |   |   |   |   | Page |
| Part                  I                        | Financial                  Information | 3 |
|                                           |   |   |   |   |   |   |   |   |
| Item                  1.                       | Financial                  Statements: | 3 |
|                                           |   |   |   |   |   |   |   |   |
|                                           | Condensed                  Balance Sheets June 30, 2006 (unaudited) and December 31, 2005 |  3 |
|                                           |   |   |
|                                           | Unaudited                  Condensed Statements of Operations for the three and                  six months ended June 30, 2006 and 2005, and cumulative from                  inception                  on July 16, 1998 through June 30, 2006 |  4 |
|                                           |   |   |
|                                           | Unaudited                  Condensed Statements of Cash Flows for the six                  months ended June 30, 2006 and 2005, and cumulative from inception                  on                  July 16, 1998 through June 30, 2006 |  5 |
|                                           |   |   |
|                                           | Statement                  of Stockholders' equity for the period from July 16, 1998 to June 30,                  2006 (unaudited) |  6 |
|                                           |   |   |
|                                           |  Notes                  to Financial Statements (unaudited) |  7 |
|                                           |   |   |
| Item                  2.                       |  Plan                  of operation |  7 |
|                                           |   |   |
|  Part                  II                 |  Other                  Information |  7 |
|                                           |   |   |
|  Item                  1.                 |  Legal                  Proceedings |  7 |
|                                           |   |   |
|  Item                  2.                 |  Changes                  in Securities |  7 |
|                                           |   |   |
|  Item                  6.                 |  Exhibits                  and Reports on Form 8-K |  7 |
|                                           |   |   |
|                                           |  Signatures |  7 |
|                                           |   |   |
|                                           |  Certifications |  8                  - 10 |

----

| **A                    J&J PHARMA                    CORPORATION**                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                                                                                             |
| **CONDENSED                  BALANCE SHEETS**                                                                                                     |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   | June                  30,  |   |   | December                  31, |   |
|                                                                                                                                              |   |   | 2006 |   |   | 2005 |   |
|                                                                                                                                              |   |   | (unaudited)  |   |   |   |   |
| **ASSETS**                                                                                                                                        |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| CURRENT                  ASSETS                                                                                                                   |   | $ | - |   | $ | - |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| **LIABILITIES                  AND STOCKHOLDERS' EQUITY (DEFICIT)**                                                                               |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| CURRENT                  LIABILITIES                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|     Accounts                  payable, Officers                                                                               |   | $ | 37,188 |   | $ | 33,128 |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|     Total                  Current Liabilities                                                                                |   |   | 37,188 |   |   | 33,128 |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| STOCKHOLDERS'                  EQUITY (DEFICIT)                                                                                                   |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| Common                      stock, par value $.001, 25,000,000 shares authorized, 1,000,000                      issued and outstanding |   |   | 1,000 |   |   | 1,000 |   |
| Paid                  in capital                                                                                                                  |   |   | 1,800 |   |   | 1,800 |   |
| (Deficit)                  accumulated during the development stage                                                                               |   |   | (39,988 | ) |   | (35,928 | ) |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   |   |   |   |   |   |   |
| Total                  Stockholders' Equity (Deficit)                                                                                             |   |   | (37,188 | ) |   | (33,128 | ) |
|                                                                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                              |   | $ | -  |   | $ | - |   |

----

| **A                    J&J PHARMA                    CORPORATION** |
|------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                  |
| **CONDENSED                  STATEMENTS OF OPERATIONS**                |
| **(unaudited)**                                                        |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | from  |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 1998 |   |
|                                                                   |   |   | Three                  Months Ended  |   |   | Six                  Months Ended |   |   | (Inception) |   |
|                                                                   |   |   | June                  30,  |   |   | June                  30, |   |   | to |   |
|                                                                   |   |   | 2006 |   |   | 2005 |   |   | 2006 |   |   | 2005 |   |   | June                  30, 2006 |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| REVENUES                                                               |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| EXPENSES                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     General                  and administrative    |   |   | 1,372 |   |   | 1,291 |   |   | 4,060 |   |   | 3,746 |   |   | 39,988 |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|     Total                  expenses                |   |   | 1,372 |   |   | 1,291 |   |   | 4,060 |   |   | 3,746 |   |   | 39,988 |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS)                                            |   | $ | (1,372 | ) | $ | (1,291 | ) | $ | (4,060 | ) | $ | (3,746 | ) | $ | (39,988 | ) |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS) PER SHARE                                  |   |   | * |   |   | * |   |   | * |   |   | * |   |   |   |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| WEIGHTED                  AVERAGE NUMBER OF                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| COMMON                  SHARES OUTSTANDING                             |   |   | 1,000,000 |   |   | 1,000,000 |   |   | 1,000,000 |   |   | 1,000,000 |   |   |   |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| *                  less than $ (0.01) per share                        |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| **A                    J&J PHARMA                    CORPORATION**                       |
|----------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE                  ENTERPRISE)**                       |
| **CONDENSED                  STATEMENTS OF CASH FLOWS**                                      |
| **(unaudited)**                                                                              |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|                                                                                         |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                                                         |   |   |   |   |   |   |   |   | from  |   |
|                                                                                         |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                                                         |   |   |   |   |   |   |   |   | 1998 |   |
|                                                                                         |   |   | Six                  Months Ended  |   |   | (Inception) |   |
|                                                                                         |   |   | June                  30,  |   |   | to |   |
|                                                                                         |   |   | 2006 |   |   | 2005 |   |   | June                  30, 2006 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **OPERATING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Net                  (loss) from operations                          |   | $ | (4,060 | ) | $ | (3,746 | ) | $ | (39,988 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH (USED BY) OPERATING ACTIVITIES**                                 |   |   | (4,060 | ) |   | (3,746 | ) |   | (39,988 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **FINANCING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Shareholder                  advances                                |   |   | 4,060 |   |   | 3,746 |   |   | 37,188 |   |
|     Proceeds                  from                  sale of common stock |   |   | -  |   |   | -  |   |   | 2,800 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH PROVIDED BY FINANCING ACTIVITIES**                               |   |   | 4,060 |   |   | 3,746 |   |   | 39,988 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  INCREASE IN CASH**                                                    |   |   | (0 | ) |   | 0 |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  BEGINNING OF PERIOD**                                               |   |   | -  |   |   | -  |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  END OF PERIOD**                                                     |   | $ | (0 | ) | $ | 0 |   | $ | - |   |

----

| **A                  J&J PHARMA CORPORATION**                             |
|-------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                         |
| **STATEMENTS                  OF STOCKHOLDERS' EQUITY (DEFICIT)**             |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   | **(Deficit)**  |   |   |   |   |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   | **Accumulated**  |   |   |   |   |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   | **During                  the**  |   |   |   |   |
|                                                                          |   |   | **Common                  Stock**  |   |   | **Paid-in** |   |   | **Development** |   |   |   |   |
|                                                                          |   |   | **Shares**  |   |   | **Amount** |   |   | **Capital** |   |   | **Stage** |   |   | **Total** |   |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  at inception**                                   |   |   | - |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   |
| July                  16, 1998:                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds                    from sale of common stock at $.01 per share  |   |   | 200,000 |   |   | 200 |   |   | 1,800 |   |   |   |   |   | 2,000 |   |
| Proceeds                    from sale of common stock at par value $.001 |   |   | 800,000 |   |   | 800 |   |   |   |   |   |   |   |   | 800 |   |
|  Net                  (loss) for the period                              |   |   | -  |   |   | -  |   |   | -  |   |   | (2,385 | ) |   | (2,385 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 1998**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (2,385 | ) |   | 415 |   |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 1999**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (5,370 | ) |   | (2,570 | ) |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2000**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (8,355 | ) |   | (5,555 | ) |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (5,685 | ) |   | (5,685 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2001**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (14,040 | ) |   | (11,240 | ) |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (4,335 | ) |   | (4,335 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2002**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (18,375 | ) |   | (15,575 | ) |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (4,358 | ) |   | (4,358 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2003**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (22,733 | ) |   | (19,933 | ) |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (6,605 | ) |   | (6,605 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2004**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (29,338 | ) |   | (26,538 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net                  (loss) for the year                                |   |   | -  |   |   | -  |   |   | -  |   |   | (6,590 | ) |   | (6,590 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2005**                              |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (35,928 | ) |   | (33,128 | ) |
| **(unaudited)**                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net                  (loss) for the period                              |   |   | -  |   |   | -  |   |   | -  |   |   | (4,060 | ) |   | (4,060 | ) |
|                                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  June 30, 2006 (unaudited)**                      |   |   | 1,000,000 |   | $ | 1,000 |   | $ | 1,800 |   | $ | (39,988 | ) | $ | (37,188 | ) |

----

| 31.1 | Certificate                  of CEO as Required by Rule                  13a-14(a)/15d-14 |
|------|-------------------------------------------------------------------------------------------|

| 31.2 | Certificate                  of CFO as Required by Rule                  13a-14(a)/15d-14 |
|------|-------------------------------------------------------------------------------------------|

| 32 | Certificate                  of CEO & CFO as Required by Rule Rule 13a-14(b) and Rule 15d-14(b) (17                  CFR 240.15d-14(b)) and Section 1350 of Chapter 63 of Title 18 of                  the                  United States Code |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                  such disclosure controls and procedures, or caused such disclosure                  controls and procedures to be designed under our supervision, to                  ensure                  that material information relating to the small business issuer,                  including                  its consolidated subsidiaries, is made known to us by others within                  those                  entities, particularly during the period in which this report is                  being                  prepared; |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Designed                  such internal control over financial reporting, or caused such                  internal                  control over financial reporting to be designed under our supervision,                  to                  provide reasonable assurance regarding the reliability of financial                  reporting and the preparation of financial statements for external                  purposes in accordance with generally accepted accounting                  principles; |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)  | Evaluated                  the effectiveness of the small business issuer's disclosure controls                  and                  procedures and presented in this report our conclusions about the                  effectiveness of the disclosure controls and procedures, as of                  the end of                  the period covered by this report based on such evaluation;                  and |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)  | Disclosed                  in this report any change in the small business issuer's internal                  control                  over financial reporting that occurred during the small business                  issuer's                  most recent fiscal quarter (the small business issuer's fourth                  fiscal                  quarter in the case of an annual report) that has materially affected,                  or                  is reasonably likely to materially affect, the small business issuer's                  internal control over financial reporting;                  and |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)  | All                  significant deficiencies and material weaknesses in the design                  or                  operation of internal control over financial reporting which are                  reasonably likely to adversely affect the small business issuer's                  ability                  to record, process, summarize and report financial information;                  and |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Any                  fraud, whether or not material, that involves management or other                  employees who have a significant role in the small business issuer's                  internal control over financial                  reporting. |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                    such disclosure controls and procedures, or caused such disclosure                    controls and procedures to be designed under our supervision,                    to ensure                    that material information relating to the small business issuer,                    including                    its consolidated subsidiaries, is made known to us by others                    within those                    entities, particularly during the period in which this report                    is being                    prepared; |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Designed                    such internal control over financial reporting, or caused such                    internal                    control over financial reporting to be designed under our supervision,                    to                    provide reasonable assurance regarding the reliability of financial                    reporting and the preparation of financial statements for external                    purposes in accordance with generally accepted accounting                    principles; |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)  | Evaluated                    the effectiveness of the small business issuer's disclosure controls                    and                    procedures and presented in this report our conclusions about                    the                    effectiveness of the disclosure controls and procedures, as of                    the end of                    the period covered by this report based on such evaluation;                    and |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)  | Disclosed                    in this report any change in the small business issuer's internal                    control                    over financial reporting that occurred during the small business                    issuer's                    most recent fiscal quarter (the small business issuer's fourth                    fiscal                    quarter in the case of an annual report) that has materially                    affected, or                    is reasonably likely to materially affect, the small business                    issuer's                    internal control over financial reporting;                    and |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)  | All                    significant deficiencies and material weaknesses in the design                    or                    operation of internal control over financial reporting which                    are                    reasonably likely to adversely affect the small business issuer's                    ability                    to record, process, summarize and report financial information;                    and |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)  | Any                    fraud, whether or not material, that involves management or other                    employees who have a significant role in the small business issuer's                    internal control over financial                    reporting. |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----